GU Cancers 2020 | KEYNOTE-921: pembrolizumab + docetaxel & prednisone for mCRPC
VJOncology is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, discusses the KEYNOTE-921 study (NCT03834506) of pembrolizumab plus docetaxel and prednisone for enzalutamide or abiraterone acetate for patients with metastatic CRPC. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.
Get great new content delivered to your inboxSign up